DGI044 table 1
| TAT (drugs) | N° patients (%) |
|---|---|
| Alemtuzumab | 1 (0.19) |
| Bevacizumab | 110 (20.52) |
| Cetuximab | 80 (14.93) |
| Ipilimumab | 4 (0.75) |
| Panitumumab | 5 (0.93) |
| Rituximab | 76 (14.18) |
| Trastuzumab | 104 (19.48) |
| Dasatinib | 10 (1.86) |
| Erlotinib | 49 (9.14) |
| Gefitinib | 6 (1.12) |
| Imatinib | 53 (9.90) |
| Lapatinib | 20 (3.73) |
| Nilotinib | 6 (1.12) |
| Sorafenib | 8 (1.49) |
| Sunitinib | 22 (4.10) |
| Bortezomib | 15 (2.80) |